NCT02465060 2026-04-13Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting6,452 enrolled 2 FDA
NCT03667716 2025-01-17COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.Compugen LtdPhase 1 Completed121 enrolled